美女免费一级视频在线观看

BridgeBio Pharma’s stock jumped more than 6% on Thursday after the drugmaker announced promising sales results for its FDA-approved heart drug as part of its latest quarterly earnings release.

The near-complete TTR stabilizer drug, Attruby, has been prescribed by 516 unique prescribers and reached 1,028 unique patient prescriptions since getting the regulatory greenlight on November 22. 

The FDA approved the drug to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients.

Per data released by the company, the drug reduced all-cause mortality by 42% and cardiovascular hospitalizations at 30 months by 50%. 

The clinical and financial achievements of Attruby were celebrated by BridgeBio’s leadership team in a statement. 

“I am very encouraged by the strength of the Attruby launch, with prescriptions being successfully filled across all patient types,” said Matt Outten, chief commercial officer of BridgeBio, in a statement. “Combined with our industry-leading patient support programs, we believe Attruby is delivering a much-needed change in the treatment landscape.”

That news sent BridgeBio’s stock higher during the first few hours of trading Thursday, though the company’s stock has been on an upward trajectory since the beginning of the year.

Year-to-date, BridgeBio’s stock is up nearly 30%, signaling the company’s continued momentum in the cardiovascular treatment space.  

While the drugmaker touted its positive returns from Attruby, it still trails behind Pfizer’s Tafamidis, the other drug used to treat ATTR cardiomyopathy, which generated $5 billion in sales last year

Both BridgeBio’s Attruby and Pfizer’s Tafamidis work to treat transthyretin amyloid cardiomyopathy. They are both designed to prevent the misfolding of TTR monomers that, if built up in the heart, can lead to heart failure. 

However, they both work slightly differently — Attruby mimics the natural mutation of the TTR gene while tafamidis binds to the TTR at the thyroxine binding sites. 

Clinical trials results have shown that Tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations while also slowing a decline in quality of life and functional capacity.

Tafamidis also has been noted to have minimal side effects in healthy adults, while Attruby’s side effects may include diarrhea and abdominal pain. 

The biggest concern around Attruby is how it will continue to fare up against Tafamidis, as well as other emerging drugs on the market. 

Alnylam Pharmaceuticals currently has Amvuttra, its drug targeting ATTR amyloidosis with cardiomyopathy, under FDA review. 

Amvuttra is seen as a competitor to Attruby since the drug works to silence the gene responsible for producing abnormal TTR proteins, which can build up and cause heart problems. 

The drug has been noted as a more targeted approach since it aims to approach the underlying cause of the disease. 

In addition to its domestic regulatory success, Attruby was also approved for use in the EU under the name Beyonttra on February 10. BridgeBio received a $75 million milestone payment and will stand to receive ongoing royalties. 

In addition to the success of Attruby, BridgeBio also announced a boost in its financial standing, with its cash equivalents totaling $681.2 million at the end of December. This is more than double what it was in December 2023. 

The increase in cash is primarily attributable to the net proceeds from a funding agreement, a term loan and various equity financings.

Earlier this year, BridgeBio secured up to $1.25 billion in capital from Blue Owl Capital and Canada Pension Plan Investment Board to accelerate the development and launch of genetic medicines.

The company also said its currently working on a few other therapies which are currently in pipeline, such as drugs to reduce muscular dystrophy type 2, a calcium sensing receptor antagonist in development for autosomal dominant hypocalcemia type 1 and a FGFR1-3 inhibitor in development for achondroplasia and hypochondroplasia.